**Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Iron Deficiency and Chronic Heart Failure (EFFECT-HF): A Randomized, Controlled Study**

**Purpose:** To study the effects of treating iron deficiency (ID) in chronic heart failure patients with intravenous (iv) ferric carboxymaltose (FCM).

**Trial Design:** Prospective, randomized 1:1; controlled, open-label, international, multicenter, 2-arms; 172 stable, mild-moderate HF patients (NYHA II-III) with reduced exercise capacity were randomized (1:1) to either iv FCM or Standard of Care (SoC) for 24 weeks.

**Primary Endpoint:** peakVO2 at 24 weeks

**Trial Results**

**Conclusions:** Peak VO2 improved in patients who received FCM